PET scan to check early response to immunotherapy before lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a special PET scan (68Ga-grazytracer) to see if it can predict early whether immunotherapy is working in people with lung cancer that can be surgically removed. If successful, this scan could help doctors tailor treatment sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IB to IIIA non-small cell lung cancer that can be surgically removed.
- You are between 18 and 75 years old.
- You are in good enough health to walk and take care of yourself (ECOG 0 or 1).
- You have not had cancer before, or if you have, it was cured at least 2 years ago and needs no further treatment.
- You do not have an active autoimmune disease or take steroids/immune-suppressing drugs.
- You are not pregnant or breastfeeding.
- You do not have uncontrolled diabetes or high blood sugar on the day of the scan.
- You do not have serious heart, bone marrow, liver, or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
This trial tests a new type of PET scan that uses a special tracer to find lung tumors. The goal is to see if this scan can better detect cancer cells, which may help doctors plan the best treatment for you.
This study tests if a new type of PET scan can see changes in your immune system when you receive immunotherapy for non-small cell lung cancer. It may help doctors understand how well your treatment is working.
This trial uses a special scan (68Ga-grazytracer PET) to see how well immunotherapy works for stage III non-small cell lung cancer before surgery or radiation. It aims to help doctors choose the best treatment for you.
This trial uses a special PET scan (68Ga-grazytracer) to find out whether growth seen on scans after immunotherapy is real cancer growth or a harmless reaction called pseudoprogression. It helps doctors decide if your treatment is working.
This trial uses a special PET scan called 68Ga-grazytracer to see how well immunotherapy is working in people with stomach, colon, or other gastrointestinal cancers. The goal is to find out if this scan can help doctors track your response to treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.